Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,064 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $51,306.08. Following the completion of the transaction, the senior vice president now directly owns 4,232 shares of the company’s stock, valued at approximately $204,067.04. The trade was a 20.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $51.23 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $53.49. The company’s 50 day moving average price is $44.61 and its 200-day moving average price is $42.17. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same quarter last year, the company earned ($0.57) EPS. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Leerink Partners boosted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup boosted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $57.10.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $10,611,000. Aigen Investment Management LP bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $320,000. Charles Schwab Investment Management Inc. lifted its position in Mirum Pharmaceuticals by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,639 shares of the company’s stock valued at $13,755,000 after purchasing an additional 4,478 shares during the period. Jones Financial Companies Lllp boosted its holdings in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after purchasing an additional 357 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Mirum Pharmaceuticals by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 124,328 shares of the company’s stock worth $5,141,000 after purchasing an additional 9,629 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.